8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Geographic Variations in the Incidence of Glioblastoma and Prognostic Factors Predictive of Overall Survival in US Adults from 2004–2013

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: The purpose of this study was to evaluate variations in the regional incidence of glioblastoma in US adults in 2004–2013.

          Study Design and Setting: We evaluated 24,262 patients with primary glioblastoma. Data were categorized based on geographic regions that included different SEER registry sites as follows: (1) Northeast: Connecticut, New Jersey (3,977 patients); (2) South: Kentucky, Louisiana, Metropolitan Atlanta, Rural Georgia, Greater Georgia (excluding AT and RG) (5,212 patients); (3) North Central: Metropolitan Detroit, Iowa (2,320 patients); (4) West: Hawaii, New Mexico, Seattle (Puget Sound), Utah, San Francisco-Oakland SMSA, San Jose-Monterey, Los Angeles, Greater California (excluding SF, LA, and SJ), Alaska (12,753 patients).

          Results: Statistically significant differences in the rates of overall patient survival ( P < 0.001) and the incidence of glioblastoma (24.31, 22.6, 20.35, 15.03 per 100,000/year in the South, Northeast, West, North Central regions, respectively) were identified between geographic regions. Multivariate Cox regression analysis demonstrated that overall survival was better in patients of Asian or Pacific Islander race. In addition, age, registry site, marital status, tumor laterality, histological classification, the extent of disease, tumor size, tumor extension, and treatment methods were identified as significant prognostic factors.

          Conclusion: Glioblastoma incidence is geographic region and race/ethnicity–dependent.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

          A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy. (Funded by Gateway for Cancer Research and others; ClinicalTrials.gov number, NCT02208362 .).
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Temozolomide resistance in glioblastoma multiforme

              Sang Lee (2016)
              Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Aging Neurosci
                Front Aging Neurosci
                Front. Aging Neurosci.
                Frontiers in Aging Neuroscience
                Frontiers Media S.A.
                1663-4365
                07 November 2017
                2017
                : 9
                : 352
                Affiliations
                Department of Neurosurgery, Huashan Hospital Shanghai Medical College, Fudan University , Shanghai, China
                Author notes

                Edited by: Philip P. Foster, University of Texas Health Science Center at Houston, United States

                Reviewed by: Neha Sehgal, Children's Hospital of Philadelphia, United States; Dinorah Friedmann-Morvinski, Tel Aviv University, Israel; Eric D. Laywell, Florida State University College of Medicine, United States

                *Correspondence: Zhiyong Qin wisdomqin@ 123456vip.163.com
                Article
                10.3389/fnagi.2017.00352
                5681990
                29163134
                47d619ec-c04f-45bb-94af-495706972d75
                Copyright © 2017 Xu, Chen, Xu and Qin.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 03 January 2017
                : 17 October 2017
                Page count
                Figures: 2, Tables: 2, Equations: 0, References: 47, Pages: 9, Words: 6241
                Categories
                Neuroscience
                Original Research

                Neurosciences
                ethnicity,geographic region,glioblastoma,prognosis,surveillance,epidemiology,end results (seer) program

                Comments

                Comment on this article